Role of Pharmacogenomics in Drug Development – An Industry ...
Role of Pharmacogenomics in Drug Development – An Industry ... Role of Pharmacogenomics in Drug Development – An Industry ...
No Samples, No Science• Clinical trial pharmacogenetics requires the prospectivecollection of samples and data• Samples should be collected even in situations where studyphenotype(s) are not yet identified• Requires appropriate informed consent• Reduces potential misrepresentation of the clinical trialpopulation and sample bias that may occur when samplesare collected retrospectively• DNA collection and storage enables pharmacogenetic studywhen new biological information emerges, even after studyhas completed• As illustrated ………
PPARγ agonist FarglitazarOedema AE PGx• PPARγ agonists are clinically effective treatments ofType 2 Diabetes• Most common side effects are fluid retention/oedema,can range from inconvenient to clinical concernrequiring discontinuation• Mechanism and optimal management not fullyunderstood
- Page 1 and 2: Role of Pharmacogenomics inDrug Dev
- Page 3 and 4: Variation in medicine response to c
- Page 5 and 6: GSK Pharmacogenetic StrategyOngoing
- Page 7 and 8: Efficacy PGx: Opportunities• Asso
- Page 9 and 10: APOE4 - a susceptibility gene varia
- Page 11 and 12: ADAS-Cog Score in APOE ε4-Negative
- Page 13 and 14: Rosiglitazone in ADPhase III progre
- Page 15 and 16: Abacavir and Hypersensitivity (HSR)
- Page 17: Abacavir HSR Prospective PGx study
- Page 21 and 22: Farglitazar oedema AE PGxSCNN1B Gen
- Page 23 and 24: Ethical considerations• PGx is no
PPARγ agonist FarglitazarOedema AE PGx• PPARγ agonists are cl<strong>in</strong>ically effective treatments <strong>of</strong>Type 2 Diabetes• Most common side effects are fluid retention/oedema,can range from <strong>in</strong>convenient to cl<strong>in</strong>ical concernrequir<strong>in</strong>g discont<strong>in</strong>uation• Mechanism and optimal management not fullyunderstood
Change language